The Board of Indoco Remedies approved the re-appointment of Ms. Aditi Panandikar as Managing Director for a five-year term, ensuring leadership continuity for the pharmaceutical firm. The tenure is scheduled to commence on February 15, 2027, and conclude on February 14, 2032, pending final approval from shareholders at the company’s 79th Annual General Meeting. This decision follows recommendations from the Nomination and Remuneration Committee and was ratified during a board meeting held on July 28, 2026.

In a concurrent move to strengthen its senior management structure, the Board also appointed Mr. Sudhir Kadam as Senior Management Personnel, designated as Senior Vice President (Human Capital). His appointment took effect immediately on July 28, 2026, marking a strategic addition to the executive team responsible for human resources and organizational development.

Key Appointments

Ms. Panandikar, who holds a Master’s Degree in Pharmaceutical Administration from Ohio State University, brings over 30 years of experience in domestic marketing, human resources, technical functions including R&D and QA, and business development. As the daughter of Mr. Suresh G Kare, the Company’s Chairman, she has been integral to the organization’s techno-commercial strategy. The filing confirms that she is not debarred from holding office by SEBI or any other authority.

Mr. Kadam joins with a robust background in human resource management, holding a Master’s Degree in Management Studies (Human Resources) from Sydenham Institute of Management Studies and Research, Mumbai University. With three decades of experience across pharma, automotive, farm equipment, and engineering sectors, he will oversee strategic HR, talent management, and leadership development initiatives.

Regulatory Compliance

The announcements were made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part-A of Schedule III. The disclosures align with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The Board meeting commenced at 10:45 a.m. and concluded at 11:45 a.m. on July 28, 2026.

Leadership Continuity

The re-appointment of Ms. Panandikar underscores the Board’s confidence in her long-standing leadership, which has spanned multiple critical functions within the company. Her dual expertise in pharmaceutical administration and commercial operations positions her to navigate the evolving regulatory and market landscapes in the healthcare sector. The simultaneous appointment of Mr. Kadam signals a focus on strengthening internal capabilities, particularly in talent acquisition and retention, which are vital for sustaining growth in a competitive industry. Shareholders will have the opportunity to vote on Ms. Panandikar’s re-appointment at the upcoming annual general meeting.

Indoco Remedies Limited will conduct an earnings conference call on July 28, 2026, to discuss the unaudited financial results for the quarter ended June 30, 2026. The meeting is scheduled to begin at 3:30 PM IST, providing investors and analysts with an opportunity to review the company's performance for Q1 FY2026-2027.

The announcement was made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was submitted to the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited for information and dissemination.

The conference call will be represented by key members of the company's leadership team. Attendees include Ms. Aditi Panandikar, Managing Director; Mr. Sundeep V. Bambolkar, Joint Managing Director; and Mr. Pramod Ghorpade, Chief Financial Officer.

Participants are encouraged to pre-register using the provided DiamondPass link to avoid waiting queues. The company has provided universal access numbers for domestic participants and international toll-free lines for investors in Hong Kong, Singapore, the USA, and the UK.

For further inquiries regarding the earnings call, stakeholders may contact representatives from Dolat Capital Market Pvt. Ltd., including Rashmi Shetty, Candice Pereira, and Zain Gulam Hussain.

Conference Call Details